Canadian guidelines for treatment of non-muscle invasive bladder cancer: A focus on intravesical therapy

Journal of the Canadian Urological Association

Volumn 4, Issue 3, 2010, Pages 168-173

  Kassouf, Wassim ^a   Kamat, Ashish M ^b   Zlotta, Alexander ^c   Bochner, Bernard H ^d   Moore, Ronald ^e   So, Alan ^f   Izawa, Jonathan ^g   Rendon, Ricardo A ^h   Lacombe, Louis ⁱ   Aprikian, Armen G ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e UNIVERSITY OF ALBERTA   (Canada)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^g UNIVERSITY OF WESTERN ONTARIO   (Canada)

^h DALHOUSIE UNIVERSITY   (Canada)

ⁱ LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77953719948     PISSN: 19116470     EISSN: 19116470     Source Type: Journal    
DOI: 10.5489/cuaj.10051     Document Type: Article

References (71)

1. Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005;66:4-34.
2. Chow WH, Lindblad P, Gridley G, et al. Risk of urinary tract cancers following kidney or ureter stones. Natl Cancer Inst 1997;89:1453-7.
3. Kantor AF, Hartge P, Hoover RN, et al. Urinary tract infection and risk of bladder cancer, Am J Epidemiol 1984;119:510-5.
4. Fioriti D, Pietropaolo V, Dal Forno S, et al. Urothelial bladder carcinoma and viral infections: different association with human polyomaviruses and papillomaviruses. Int] Immunopathol Pharmacol 2003;16:283-8.
5. Mostafa MH, Sheweita SA, O'Connor PJ. Relationship between schistosomiasis and bladder cancer. Clin Microbiol Rev 1999; 2:97-111.
6. Cannon J, Linke CA, Cos LR. Cyclophosphamide-associated carcinoma of urothelium: modalities for prevention. Urology 1991;38:413-6.
7. Kaldor JM, Day NE, Kittelmann B, et al. Bladder tumours following chemotherapy and radiotherapy for ovarian cancer: a case-control study. Int J Cancer 1995;63:l-6.
8. Clayson DB. Specific aromatic amines as occupational bladder carcinogens. Natl Cancer Inst Monogr 1981;(58):15-9.
9. Droller Ml. Alterations of the p53 gene in occupational bladder cancer in workers exposed to aromatic amines. J Urol 1998;160:618.
10. Piper JM, Tonascia J, Matanoski GM. Heavy phenacetin use and bladder cancer in women aged 20 to 49years. N Engl J Med 1985;313:292-5.
11. Heney NM. Natural history of superficial bladder cancer. Prognostic features and long-term disease course. Urol Clin North km 1992;19:429-33.
12. Botteman MF, Pashos CL, Redaelli A, et al. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 2003;21:1315-30.
13. Avritscher EB, Cooksley CD, Grossman HB, et al. Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology 2006;68:549-53.
14. Babjuk M, Oosterlinck W, Sylvester R, et al. EAU Guidelines on Non-Muscle-lnvasive Urothelial Carcinoma of the Bladder. Eur Urol 2008;54:303-14.
15. Montie JE, Abrahams NA, Bahnson RR, et al. Bladder cancer. Clinical guidelines in oncology. J Natl Compr Cane Netw 2006;4:984-1014.
16. Hall MC, Chang SS, Dalbagni G, et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, Tl, and Tis): 2007 update. J Urol 2007;178:2314-30.
17. Zlotta AR, van Vooren JP, Huygen K, et al. What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary? Eur Urol 2000;37:470-7.
18. Soloway MS. Overview of treatment of superficial bladder cancer. Urology 1985;26:18-26.
19. Holmang S, Hedelin H, Anderstrom C, et al. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and Tl transitional cell cancer of the bladder followed for at least 20 years. I Urol 1995; 153:1823-6.
20. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, et al. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. I Urol 2000;163:73-8.
21. Flamm J, Havelec L. Factors affecting survival in primary superficial bladder cancer. Eur Urol 1990; 17:113-8.
22. van der Heijden AG, Kiemeney LA, Gofrit ON, et al. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol 2004;46:65-71.
23. Lutzeyer W, Rubben H, Dahm H. Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. I Urol 1982;127:250-2.
24. Herr HW. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy. I Urol 2005;174:2134-7.
25. Filbeck T, Pichlmeier U, Knuechel R, et al. Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumours. J Urol 2002;168:67-71.
26. Daniltchenko Dl, Riedl CR, Sachs MD, et al. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. I Urol 2005;174:2129-33.
27. Herr HW. The value of a second transurethral resection in evaluating patients with bladder tumours. I Urol 1999;162:74-6.
28. Schips L, Augustin H, Zigeuner RE, et al. Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer? Urology 2002;59:220-3.
29. Grimm M0, Steinhoff C, Simon X, et al. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. I Urol 2003;170:433-7.
30. Fitzpatrick JM, West AB, Butler MR, et al. Superficial bladder tumours (stage pTa, grades 1 and 2): the importance of recurrence pattern following initial resection. I Urol 1986;135:920-2.
31. Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta Tl bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004;1 71:2186-90.
32. Kaasinen E, Rintala E, Hellstrom P, et al. Factors explaining recurrence in patients undergoing chemoim-munotherapy regimens for frequently recurring superficial bladder carcinoma. Eur Urol 2002;42:167-74.
33. Nieuwenhuijzen JA, Bex A, Horenblas S. Unusual complication after immediate postoperative intravesical mitomycin C instillation. Eur Urol 2003;43:711-2.
34. Oddens JR, van der Meijden AP, Sylvester R. One immediate postoperative instillation of chemotherapy in low risk Ta, Tl bladder cancer patients. Is it always safe? ft/r fro/ 2004;46:336-8.
35. Racioppi M, Porreca A, Foschi N, et al. Bladder perforation: a potential risk of early endovesical chemotherapy with mitomycin C. Wro/ /of 2005;75:373-5.
36. Au JL, Badalament RA, Wientjes MG, et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. I Natl Cancer Inst 2001;93:597-604.
37. Huncharek M, Geschwind JF, Witherspoon B, et al. Intravesical chemotherapy prophylaxis in primary superficial bladder cancer: a meta-analysis of 3703 patients from 11 randomized trials. I Clin Epidemiol 2000;53:676-80.
38. Huncharek M, McGarry R, Kupelnick B. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis. Anticancer Res 2001;21:765-9.
39. Lamm DL, Riggs DR, Traynelis CL, et al. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. I Urol 1995;153:1444-50.
40. Lamm DL Bacillus Calmette-Guerin immunotherapy for bladder cancer. I Urol 1985;134:40-7.
41. Nseyo U0, Lamm DL. Immunotherapy of bladder cancer. Semin Surg Oncol 1997;13:342-9.
42. Herr HW, Pinsky CM, Whitmore WF Jr, et al. Experience with intravesical bacillus Calmette-Guerin therapy of superficial bladder tumours. Urology 1985;25:119-23.
43. Herr HW. Transurethral resection and intravesical therapy of superficial bladder tumours. Urol Clin North Am 1991;18:525-8.
44. Pagano F, Bassi P, Milani C, et al. A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: is it effective? I Urol 1991;146:32-5.
45. Melekos MD, Chionis H, Pantazakos A, et al. Intravesical bacillus Calmette-Guerin immunoprophylaxis of superficial bladder cancer: results of a controlled prospective trial with modified treatment schedule. I Urol 1993;149:744-8.
46. Krege S, Giani G, Meyer R, et al. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics. I Urol 1996; 156:962-6.
47. Huncharek M, Kupelnick B. Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: metaanalytic reevaluation. Am J Clin Oncol 2003;26:402-7.
48. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. I Urol 2002;168:1964-70.
49. Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. I Urol 2003;169:90-5.
50. Shelley MD, Wilt TJ, Court J, et al. Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials. BJU Int 2004;93:485-90.
51. Bohle A, Bock PR. Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumour progression. Urology 2004;63:682-6.
52. Sylvester RJ, van der Meijden AP, Witjes JA, et al. Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. I Urol 2005;174:86-91.
53. Sternberg CN, Yagoda A, Scher HI, et al. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. I Urol 1988;139:461-9.
54. Cookson MS, Herr HW, Zhang ZF, et al. The treated natural history of high risk superficial bladder cancer: 15-year outcome. I Urol 1997;158:62-7.
55. Lamm DL. Carcinoma in situ. Urol Clin North Am 1992;19:499-508.
56. Sylvester RJ, van der Meijden AP, Witjes JA, et al. High-grade Ta urothelial carcinoma and carcinoma in situ of the bladder. Urology 2005;66:90-107.
57. Takenaka A, Yamada Y, Miyake H, et al. Clinical outcomes of bacillus Calmette-Guerin instillation therapy for carcinoma in situ of urinary bladder. IntI Urol 2008;15:309-13.
58. Herr HW, Wartinger DD, Fair WR, et al. Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year followup. I Urol 1992;147:1020-3.
59. Kavoussi LR, Torrence RJ, Gillen DP, et al. Results of 6 weekly intravesical bacillus Calmette-Guerin instillations on the treatment of superficial bladder tumours. J Urol 1988;139: 935-40.
60. Bretton PR, Herr HW, Kimmel M, et al. The response of patients with superficial bladder cancer to a second course of intravesical bacillus Calmette-Guerin. J Urol 1990;143:710-2.
61. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, Tl and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000;163:1124-9.
62. Losa A, Hurle R, Lembo A. Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results. I Urol 2000;163:68-71.
63. Mack D, Frick J. Five-year results of a phase II study with low-dose bacille Calmette-Guerin therapy in high-risk superficial bladder cancer. Urology 1995;45:958-61.
64. Herr HW, Dalbagni G. Defining bacillus Calmette-Guerin refractory superficial bladder tumours. I Urol 2003;169:1706-8.
65. Bui TT, Schellhammer PF. Additional bacillus Calmette-Guerin therapy for recurrent transitional cell carcinoma after an initial complete response. Urology 1997;49:687-90.
66. Catalona WJ, Hudson MA, Gillen DP, et al. Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. I Urol 1987;137:220-4.
67. Herr HW, Sogani PC. Does early cystectomy improve the survival of patients with high risk superficial bladder tumours? I Urol 2001;166:1296-9.
68. Joudi FN, Smith BJ, 0'Donnell MA. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 2006;24:344-8.
69. O'Donnell MA, Lilli K, Leopold C. Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer. I Urol 2004;172:888-93.
70. Colombo R, Da Pozzo LF, Salonia A, et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. I Clin Oncol 2003;21:4270-6.
71. Di Stasi SM, Giannantoni A, Giurioli A, et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial, lancet Oncol 2006;7:43-51.